Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.84 |
| ▸ | SRC | P12931 | 9/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.68 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.67 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612969 | 0.85 | SMN1; SMN2 (0.76) | ABL1SRCSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL16971035 | 0.84 | ABL1 (1.00) | ABL1SRCSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8779355 | 0.83 | RAB9A (0.70) | ABL1SRCSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL28451175 | 0.83 | ABL1 (0.67) | ABL1SRCSMN1; SMN2NPC1RAB9A | |
| SCHEMBL601080 | 0.82 | DGAT1 (1.00) | ABL1SRCDGAT1 | |
| SCHEMBL601079 | 0.82 | DGAT1 (1.00) | ABL1SRCDGAT1 | |
| SCHEMBL8779318 | 0.82 | ABL1 (0.65) | ABL1SRCSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7483795 | 0.80 | MEN1 (0.65) | ABL1SRCSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9593578 | 0.78 | ABL1 (0.60) | ABL1SRCSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8483666 | 0.78 | ABL1 (0.59) | ABL1SRCSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0579129-B1 | Thiadiazole derivatives for the treatment of depressive states | CT LAB FARM SRL (IT) | 1997-03-05 | — | — | EP | claimed |
| EP-0579129-A2 | Thiadiazole derivatives for the treatment of depressive states | LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) | 1994-01-19 | — | — | EP | claimed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20190040448-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE GENERAL HOSPITAL CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | TUFTS MEDICAL CENTER | 2016-09-01 | — | — | US | disclosed |
| EP-0579129-B1 | Thiadiazole derivatives for the treatment of depressive states | CT LAB FARM SRL (IT) | 1997-03-05 | — | — | EP | disclosed |
| US-5401853-A | Thiadiazole derivatives for the treatment of depressive states | LABORATORIO FARMACEUTICO C.T. S.R.L. (IT) | 1995-03-28 | — | — | US | disclosed |
| EP-0579129-A2 | Thiadiazole derivatives for the treatment of depressive states | LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040448-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | ABL1 18/4885SRC 19/4885SMN1; SMN2 3745/4885 |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | ABL1 18/4885SRC 19/4885SMN1; SMN2 3745/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | ABL1 1917/4885SRC 1353/4885SMN1; SMN2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.